Kommentar
Insulin Cost Caps, Trade-Offs, and Pharmacoequity in Diabetes
JAMA · 07.07.2026 · 336 (1) · 20
DOI: 10.1001/jama.2026.7544 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA, erschienen am 07.07.2026. Verfasst von Utibe R Essien und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles. Die Arbeit nennt 15 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles.
- Center for the Study of Healthcare Innovation, Implementation and Policy, VA Greater Los Angeles Healthcare System, Los Angeles, California.
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester.
Zitieren
APA
Essien, U. R., & Byhoff, E. (2026). Insulin Cost Caps, Trade-Offs, and Pharmacoequity in Diabetes. JAMA, 336(1), 20. https://doi.org/10.1001/jama.2026.7544
Vancouver
Essien UR, Byhoff E. Insulin Cost Caps, Trade-Offs, and Pharmacoequity in Diabetes. JAMA. 2026;336(1):20. doi:10.1001/jama.2026.7544
BibTeX
@article{Essien2026,
author = {Essien, Utibe R and Byhoff, Elena},
title = {Insulin Cost Caps, Trade-Offs, and Pharmacoequity in Diabetes},
journal = {JAMA},
year = {2026},
volume = {336},
number = {1},
pages = {20},
doi = {10.1001/jama.2026.7544}
}
EUVIMED